scholarly article | Q13442814 |
P356 | DOI | 10.1002/HED.23655 |
P698 | PubMed publication ID | 24595923 |
P2093 | author name string | Alexandra Kaider | |
Christoph Arnoldner | |||
Dominik Riss | |||
Martin Burian | |||
Axel Wolf | |||
Veronika Kranebitter | |||
P2860 | cites work | The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia | Q33405788 |
Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). | Q33897059 | ||
Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose | Q34260695 | ||
Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis | Q37846178 | ||
Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis | Q37846182 | ||
Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy | Q37965478 | ||
An epistaxis severity score for hereditary hemorrhagic telangiectasia | Q48906632 | ||
Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab | Q79811356 | ||
P433 | issue | 6 | |
P921 | main subject | hereditary hemorrhagic telangiectasia | Q776881 |
placebo-controlled trial | Q108853737 | ||
placebo | Q269829 | ||
bevacizumab | Q413299 | ||
P304 | page(s) | 783-787 | |
P577 | publication date | 2014-04-30 | |
P1433 | published in | Head & Neck | Q13703062 |
P1476 | title | Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial | |
P478 | volume | 37 |
Q35336067 | Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia |
Q90427144 | Effect Of Bevacizumab On Growth Of Human Nasal Polyposis In Vitro; An Off-Label Use Of Anti-Angiogenic Agent For Nasal Polyposis Treatment |
Q36821724 | Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study |
Q27317227 | Epistaxis in hereditary hemorrhagic telangiectasia: an evidence based review of surgical management |
Q57163936 | Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective |
Q36245169 | Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT). |
Q34388065 | Optimal management of hereditary hemorrhagic telangiectasia |
Q64898571 | Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia. |
Q38374758 | Pericytes as targets in hereditary hemorrhagic telangiectasia. |
Q92421283 | Pericytes in Hereditary Hemorrhagic Telangiectasia |
Q92271765 | Risk factors for hemorrhage of brain arteriovenous malformation |
Q36416717 | Technique modifications for septodermoplasty: an illustrative case |
Q42279034 | Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report. |
Search more.